P1126: PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

por Strati, Paolo, Morschhauser, Franck, Danilov, Alexey, Cheah, Chan, Shah, Harsh, Jurczak, Wojciech, Olabode, Damilola, Meyer, Stefanie, Lim Yoon, Jeong, Arduini, Serena, Saeh, Jamal, Olsson, Richardp, Gregory, Gareth
Publicado 2023

P1141: ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANA...

por Shortt, Jake, Feldman, Tatyana, Collins, Graham, Zain, Jasmine, Khot, Amit, Seok Kim, Jin, Morschhauser, Franck, Min Kim, Tae, Roderick, Justine, Lim Yoon, Jeong, Sharma, Shringi, Saeh, Jamal, Dai, Jiale, Reyes, Ruben, Olsson, Richardp, Luigi Zinzani, Pier
Publicado 2023

P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY

por Desai, Pinkal, Lonial, Sagar, Cashen, Amanda, Kamdar, Manali, Blachly, James S., Flinn, Ian W., O’brien, Susan, Garcia, Jacqueline, Korde, Neha, Moslehi, Javid, Wey, Margaret, Cheung, Patricia, Sharma, Shringi, Olabode, Damilola, Chen, Hong, Ali Syed, Firasath, Liu, Mary, Saeh, Jamal, Tibes, Raoul, Andrade, Marcio, Kadia, Tapan
Publicado 2023

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

por Hamilton, Erika P., Wang, Judy S., Oza, Amit M., Patel, Manish R., Ulahannan, Susanna V., Bauer, Todd, Karlix, Janet L., Zeron-Medina, Jorge, Fabbri, Giulia, Marco-Casanova, Paola, Moorthy, Ganesh, Hattersley, Maureen M., Littlewood, Gillian M., Mitchell, Patrick, Saeh, Jamal, Pouliot, Gayle P., Moore, Kathleen N.
Publicado 2023

P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL

por Marconi, Giovanni, Arslan, Shukaib, Fleming, Shaun, Curti, Antonio, S Blachly, James, Martinelli, Giovanni, Giovanni Della Porta, Matteo, Bajel, Ashish, Sauer, Tim, Crysandt, Martina, Pigneux, Arnaud, Konopleva, Marina, Marmor, Yotvat, Sharma, Shringi, Elgeioushi, Nairouz, Rowe, Emily, Cheung, Patricia, Jahn, Ekaterina, Saeh, Jamal, Tibes, Raoul, Zumla Cader, Fathima, Jain, Nitin
Publicado 2023

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

por Bertran-Alamillo, Jordi, Giménez-Capitán, Ana, Román, Ruth, Talbot, Sara, Whiteley, Rebecca, Floc’h, Nicolas, Martínez-Pérez, Elizabeth, Martin, Matthew J., Smith, Paul D., Sullivan, Ivana, Terp, Mikkel G., Saeh, Jamal, Marino-Buslje, Cristina, Fabbri, Giulia, Guo, Grace, Xu, Man, Tornador, Cristian, Aguilar-Hernández, Andrés, Reguart, Noemí, Ditzel, Henrik J., Martínez-Bueno, Alejandro, Nabau-Moretó, Núria, Gascó, Amaya, Rosell, Rafael, Pease, J. Elizabeth, Polanska, Urszula M., Travers, Jon, Urosevic, Jelena, Molina-Vila, Miguel A.
Publicado 2023

Design and optimisation of dendrimer-conjugated Bcl-2/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy

por Patterson, Claire M., Balachander, Srividya B., Grant, Iain, Pop-Damkov, Petar, Kelly, Brian, McCoull, William, Parker, Jeremy, Giannis, Michael, Hill, Kathryn J., Gibbons, Francis D., Hennessy, Edward J., Kemmitt, Paul, Harmer, Alexander R., Gales, Sonya, Purbrick, Stuart, Redmond, Sean, Skinner, Matthew, Graham, Lorraine, Secrist, J. Paul, Schuller, Alwin G., Wen, Shenghua, Adam, Ammar, Reimer, Corinne, Cidado, Justin, Wild, Martin, Gangl, Eric, Fawell, Stephen E., Saeh, Jamal, Davies, Barry R., Owen, David J., Ashford, Marianne B.
Publicado 2021